Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (446)	2/18/1999 9:06:00 AM
From: Apache Indian	Read Replies (3) \| Respond to of 1494

Mr. Paul Friemans reply (pretty comforting I must say) Dear Mr. ________: Thank you for your thoughtful inquiry concerning Neurobiological Technologies, Inc. (NTI) I am sure that as a longer-term investor you have experienced a great deal of frustration with our stock price. The questions you ask regarding financing can really be put into a nutshell as follows: The credibility of NTI has never truly been restored in the investors' minds following early announcements of the lack of results from a CRF trial in rheumatoid arthritis. The environment for small cap companies (under $300 million market cap) is quite difficult in the biotechnology field. Sophisticated investors have come to realize that it takes a biotechnology company up to 12 years to develop a drug, the same as large pharmaceutical companies. As a consequence, people are less and less willing to take the risk of investing in small, under-capitalized companies whose potential tends to be in the longer term. This is not unique to NTI but is endemic in the industry. I don't intend to close this company down since we have Memantine, a product which I truly believe will see the light of day in a relatively short period of time, i.e., between the next one and three years. The product has behaved well in our hands and in our corporate partner's, Merz + Co. GmbH & Co., who is in late Phase III trials for senile dementia and Alzheimer's disease. At this point in time, Merz and NTI are negotiating a major global marketing agreement with a large pharmaceutical company. I believe there is a good opportunity for such a relationship in the next few months. Such a relationship would trigger seven-figure payments to our company and a subsequent substantial stream of income through milestone payments and royalties. At this point in time, I am working diligently to secure enough financing to bridge us to that point in time and I am confident that we will succeed. I would be happy to speak with you directly if you care to call me at 510-215-8000. Thank you for sticking with us as a shareholder for the past three years. Sincerely, Paul E. Freiman